The global non-alcoholic steatohepatitis treatment market size was valued at USD 7.70 billion in 2024 and is expected to reach USD 55.52 billion by 2032, growing at a CAGR of 28.05% over the forecast period 2025-2032.
Rising global obesity, type 2 diabetes, and metabolic syndrome are driving fast expansion in the non-alcoholic steatohepatitis treatment market.
For instance, the World Health Organization reports that 16% of adults are obese and 43% of adults are overweight, therefore greatly raising the risk for non-alcoholic fatty liver disease (NAFLD) and its development into NASH.
Major causes of the NASH epidemic in the U.S. are reportedly over 38 million persons with diabetes and a 40.3% obesity rate. Funding for research has been raised by government organizations, including the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), with the FY2025 budget reaching $2.31 billion so supporting developments in diagnostics and therapeutics for progressive liver inflammation and NASH-related comorbidities.
The worldwide increase in obesity and metabolic diseases is driving a significant increase in NAFLD and NASH cases drives the non-alcoholic steatohepatitis treatment market mostly. The World Health Organization’s 2022 data show 2.5 billion adults overweight and 890 million obese, which directly correlates with the growing burden of fatty liver disease and liver fibrosis.
Reflecting the nation's high disease frequency, strong healthcare infrastructure, and early adoption of innovative technologies, the U.S. non-alcoholic steatohepatitis treatment market accounted for approximately 76% of the NA market share in 2024, valued USD 4.56 billion in 2024 and is expected to reach USD 32.55 billion by 2032 with a CAGR of 27.88% over the forecast period. Offering the first targeted medication for NASH with intermediate to advanced liver fibrosis and thereby supporting the U.S. leadership in NASH treatment market growth, the FDA's March 2024 approval of Rezdiffra (resmetirom) marks a historic moment. Government funding in clinical trials for NASH medications and the development of NAFLD treatments, with the U.S. leading in regulatory approvals and research projects, also helps to encourage these non-alcoholic steatohepatitis treatment market trends.
Drivers
Escalating Global Obesity Epidemic and Comorbid Metabolic Conditions Drive NASH Treatment Demand
The landscape of non-alcoholic steatohepatitis (NASH) treatment demand is being fundamentally changed by the substantial increase in obesity and related metabolic diseases observed globally. With 43% of adults overweight and 16% obese worldwide, the World Health Organization estimated that over 890 million adults would be obese by 2022. Direct contribution of this spike to a 32% worldwide prevalence rate of non-alcoholic fatty liver disease (NAFLD), the forerunner of NASH. Unbelievably, NASH already makes up 25–30% of NAFLD cases and is expected to be the main cause of liver transplants by 2030. The U.S. Centers for Disease Control and Prevention (CDC) underlines even further how the rising incidence of diabetes and metabolic syndrome-key risk factors for NASH continue to aggravate the disease burden.
In response, pharmaceutical companies are accelerating research, with over 78 drugs in Phase II/III clinical trials as of 2024 targeting inflammatory and fibrotic pathways. With analysts forecasting peak annual sales reaching USD 5 billion, the recent U.S. FDA clearance of Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) in March 2024 marks a significant industry milestone. As healthcare systems worldwide prepare for an increase in demand for efficient treatments to address this growing public health concern, the convergence of epidemiological trends and regulatory advances is driving unprecedented investment and innovation in the NASH treatment industry.
Restrain
Absence of Cost-Effective Treatment Protocols Constrains Market Penetration
The lack of affordable and effective treatment options remains a significant barrier to the widespread adoption of NASH therapies, particularly in low- and middle-income countries. Although the creation of new medications such as Rezdiffra gives optimism, most patients worldwide cannot afford modern therapies since their annual cost exceeds USD 32,600. Recent statistics show that 68% of NASH patients in areas with limited resources lack access to sophisticated care; hence, present guidelines still mostly advise lifestyle changes, which have little long-term success.
Only about 10% of patients achieve sustained weight loss through behavioural interventions, and off-label use of existing medications like vitamin E and pioglitazone provides only modest benefits, with histologic improvement seen in just 35-40% of cases. U.S. Medicare data emphasizes, even more, the financial load associated with advanced NASH since beneficiaries of this condition pay annual pharmaceutical expenses almost twice those of the average population. These financial and therapeutic constraints not only limit patient access but also deter healthcare professionals from implementing novel treatments, therefore limiting market development and leaving a significant number of the global NASH population underserved.
By Drug
The Vitamin E and pioglitazone segment dominated the non-alcoholic steatohepatitis treatment market, with 87% of global revenue in 2024. Strong clinical evidence and first-line management guidelines for NASH, especially in patients with insulin resistance and NASH-related comorbidities, anchor their leadership. Government and regulatory bodies such as the American Association for the Study of Liver Diseases (AASLD) have underlined a 40% increase in the accuracy of non-invasive diagnostic methods, therefore allowing early intervention with these hepatoprotective medications. Late-stage NASH pipeline candidates, including semaglutide, which has shown dose-dependent improvements in NASH resolution in Phase 2 clinical trials, further excite the NASH drugs market.
In 2024, the FDA recognized the urgent need for advanced therapies, accelerating the approval process for anti-NASH drugs and incentivizing clinical trials for NASH drugs with fast-track and breakthrough designations.
The semaglutide, a GLP-1 receptor agonist is expected to drive significant non-alcoholic steatohepatitis treatment market growth, acting both on weight loss and liver inflammation. Significant NASH resolution rates revealed by data from a 2024 Phase 2 trial position semaglutide as a future leader in the NASH treatment market. Rising obeticholic acid market candidates and continuous clinical trials for PPAR agonists for NASH and FXR agonists reflect the worldwide liver disease burden and the need for efficient liver cirrhosis prevention.
By Disease Stage
With a 35% share in 2024, NASH Stage F1 dominated the non-alcoholic steatohepatitis treatment market, reflecting the effect of enhanced early detection and government-backed screening campaigns. Early diagnosis of growing liver inflammation made possible by the CDC's enlarged metabolic disease surveillance and adoption of non-invasive diagnostics has allowed timely management with hepatoprotective medications and lifestyle modification in NASH. NIH budgets USD 2.31 billion for metabolic and digestive disease research in FY2025, supporting early intervention programs and NASH drug clinical trials.
NASH Stage F0 is projected to experience the fastest growth, driven by the integration of advanced screening in primary care and increased public health funding for NAFLD therapeutics. Early-stage detection has been given top priority by the NIH and CDC; the CDC notes a 10% increase in early-stage NASH diagnosis among adults with type 2 diabetes in 2024. The FDA's 2024 guidance supporting earlier therapeutic intervention supports these initiatives; this is expected to hasten the acceptance of anti-NASH drugs and liver fibrosis treatment in the F0 and F1 segments. Early-stage NASH treatment market trends are being highlighted by phase III trials for new NASH medications progressively enrolling F0 and F1 patients.
By Distribution Channel
Hospital pharmacies held a 62% non-alcoholic steatohepatitis treatment market share in 2024, supported by their management of complicated NASH cases, delivery of advanced therapies, and participation in key clinical trials for NASH drugs. Through post-marketing surveillance agreements with hospital pharmacies, the FDA guarantees a thorough investigation of drug-induced hepatotoxicity and efficacy of newly developed anti-NASH drugs.
Driven by accessibility, convenience, and the expansion of pharmacy networks, retail and specialty pharmacies are expected to see the most notable non-alcoholic steatohepatitis treatment market growth. Within five miles, over 67,000 American pharmacies service 88.9% of the population, so improving access to NAFLD treatments and hepatoprotective drugs.
For instance, Government projects such as the HHS grant program started in January 2025 help to support the integration of NASH treatment in retail environments, thus strengthening the NASH treatment market.
With a 78% market share in 2024, North America remains the dominant region in the non-alcoholic steatohepatitis treatment market. The high frequency of metabolic risk factors, including obesity, type 2 diabetes, and hypertension, drives the predominance of this area.
For instance, the Centers for Disease Control and Prevention (CDC) estimates that 40.3% of U.S. adults will be obese in 2024, with over 38 million Americans living with diabetes-90–95% of them type 2 diabetics. Nearly half of all U.S. adults (116 million) also have hypertension. With the U.S. reporting around 17.5 million prevalent instances of NASH in 2024, expected to climb to 23.33 million by 2030, these figures translate into a significant patient population at risk for NAFLD and NASH.
The region also benefits from a robust biopharmaceutical ecosystem, leading non-alcoholic steatohepatitis treatment companies such as Madrigal Pharmaceuticals and Novo Nordisk drive innovation in NASH medications and NAFLD treatments. The first liver-specific medication approved by the FDA recently has strengthened North America's position as a center for clinical trials for NASH drugs and regulatory advancement. The combination of high disease burden, advanced healthcare infrastructure, and rapid adoption of new therapies ensures that the U.S. non-alcoholic steatohepatitis treatment market will continue to set global benchmarks for market growth and innovation.
The Asia-Pacific region is set to experience the fastest CAGR of 30.2% of the non-alcoholic steatohepatitis treatment market, driven by both a large patient base and rapid healthcare innovation. China, in particular, stands out as the country with the highest number of NAFLD-afflicted individuals globally, with projections indicating 314.5 million cases by 2030. The country’s rapidly aging population is expected to reach 402 million people aged 60 and above by 2040, further increasing the risk for NASH and related comorbidities. India is emerging as a hub for drug innovation, with government initiatives promoting early diagnosis and advanced care.
For instance, in April 2024, Apollo Hospitals launched a dedicated Fatty Liver Clinic in Chennai equipped with state-of-the-art diagnostic and pharmacological solutions.
These developments, combined with rising economic prosperity and government investment, are fueling robust non-alcoholic steatohepatitis treatment market growth and expanding the regional market share.
Europe is experiencing significant non-alcoholic steatohepatitis treatment market growth, propelled by an aging population, rising obesity rates, and strong public health initiatives. For example, in Germany, the demand for new NASH drugs-including Lanifibranor and obeticholic acid (OCA)-is increasing, particularly in hospital settings that are adapting to the growing need for liver fibrosis treatment and progressive liver inflammation management. The shift toward generic drug alternatives and improved accessibility through retail and specialty pharmacies is also enhancing market penetration. A 2020 study published by the National Library of Medicine (NLM) found that annual direct medical expenses per NASH patient ranged from USD 402 to USD 1,321 in Europe, prompting ongoing efforts to develop cost-effective treatment pathways.
The major non-alcoholic steatohepatitis treatment companies are Madrigal Pharmaceuticals Inc., Intercept Pharmaceuticals, Inc., Galmed Pharmaceuticals Ltd, Inventiva, Galectin Therapeutics Inc., Novo Nordisk A/S, NGM Biopharmaceuticals, Inc., AbbVie Inc., The Bristol-Myers Squibb Company, Gilead Sciences, Inc., and others.
In August 2024, Shilpa Medicare shares surged over 11% to a new high following positive Phase 3 trial results for SMLNUD07 (NorUDCA), a potential treatment for Nonalcoholic Fatty Liver Disease (NAFLD), a condition with limited therapeutic options.
| Report Attributes | Details |
|---|---|
| Market Size in 2024 | USD 7.70 Billion |
| Market Size by 2032 | USD 55.52 Billion |
| CAGR | CAGR of 28.05% From 2025 to 2032 |
| Base Year | 2024 |
| Forecast Period | 2025-2032 |
| Historical Data | 2021-2023 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Drug (Vitamin E and Pioglitazone, Obeticholic Acid (OCA), Resmetirom, Lanifibranor, Semaglutide, Cenicriviroc, Aramchol, and Other Drugs) • By Disease Stage (NASH Stage F0, NASH Stage F1, NASH Stage F2, NASH Stage F3, and NASH Stage F4) • By Distribution Channel (Retail and Specialty Pharmacies, Hospital Pharmacies, and Other Pharmacies) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) |
| Company Profiles | Madrigal Pharmaceuticals Inc., Intercept Pharmaceuticals, Inc., Galmed Pharmaceuticals Ltd, Inventiva, Galectin Therapeutics Inc., Novo Nordisk A/S, NGM Biopharmaceuticals, Inc., AbbVie Inc., The Bristol-Myers Squibb Company, Gilead Sciences, Inc., and others |
Ans. The projected market size for the Non-alcoholic Steatohepatitis Treatment Market is USD 55.52 billion by 2032.
Ans: The North American region dominated the Non-alcoholic Steatohepatitis Treatment Market in 2024.
Ans. The CAGR of the Non-alcoholic Steatohepatitis Treatment Market is 28.04% during the forecast period of 2025-2032.
Ans: Escalating global obesity epidemic and comorbid metabolic conditions drive NASH treatment demand.
Ans: The Hospital Pharmacies segment dominated the Non-alcoholic Steatohepatitis Treatment Market.
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Prescription Trends by Region (2024)
5.2 Pharmaceutical Volume – Production & Usage (2024)
5.3 Healthcare Spending on NASH Treatment (2024)
5.4 Diagnostic and Screening Trends
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion plans and new Product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Non-alcoholic Steatohepatitis Treatment Market Segmentation By Drug
7.1 Chapter Overview
7.2 Vitamin E and Pioglitazone
7.2.1 Vitamin E and Pioglitazone Market Trends Analysis (2021-2032)
7.2.2 Vitamin E and Pioglitazone Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 Obeticholic Acid (OCA)
7.3.1 Obeticholic Acid (OCA) Market Trends Analysis (2021-2032)
7.3.2 Obeticholic Acid (OCA) Market Size Estimates and Forecasts to 2032 (USD Billion)
7.4 Resmetirom
7.4.1 Resmetirom Market Trends Analysis (2021-2032)
7.4.2 Resmetirom Market Size Estimates and Forecasts to 2032 (USD Billion)
7.5 Lanifibranor
7.5.1 Lanifibranor Market Trends Analysis (2021-2032)
7.5.2 Lanifibranor Market Size Estimates and Forecasts to 2032 (USD Billion)
7.6 Semaglutide
7.6.1 Semaglutide Market Trends Analysis (2021-2032)
7.6.2 Semaglutide Market Size Estimates and Forecasts to 2032 (USD Billion)
7.7 Cenicriviroc
7.7.1 Cenicriviroc Market Trends Analysis (2021-2032)
7.7.2 Cenicriviroc Market Size Estimates and Forecasts to 2032 (USD Billion)
7.8 Aramchol
7.8.1 Aramchol Market Trends Analysis (2021-2032)
7.8.2 Aramchol Market Size Estimates and Forecasts to 2032 (USD Billion)
7.9 Other Drugs
7.9.1 Other Drugs Market Trends Analysis (2021-2032)
7.9.2 Other Drugs Market Size Estimates and Forecasts to 2032 (USD Billion)
8. Non-alcoholic Steatohepatitis Treatment Market Segmentation By Disease Stage
8.1 Chapter Overview
8.2 NASH Stage F0
8.2.1 NASH Stage F0 Market Trend Analysis (2021-2032)
8.2.2 NASH Stage F0 Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3 NASH Stage F1
8.3.1 NASH Stage F1 Market Trends Analysis (2021-2032)
8.3.2 NASH Stage F1 Market Size Estimates and Forecasts to 2032 (USD Billion)
8.4 NASH Stage F2
8.4.1 NASH Stage F2 Market Trends Analysis (2021-2032)
8.4.2 NASH Stage F2 Market Size Estimates and Forecasts to 2032 (USD Billion)
8.5 NASH Stage F3
8.5.1 NASH Stage F3 Market Trends Analysis (2021-2032)
8.5.2 NASH Stage F3 Market Size Estimates and Forecasts to 2032 (USD Billion)
8.6 NASH Stage F4
8.6.1 NASH Stage F4 Market Trends Analysis (2021-2032)
8.6.2 NASH Stage F4 Market Size Estimates and Forecasts to 2032 (USD Billion)
9. Non-alcoholic Steatohepatitis Treatment Market Segmentation By Distribution Channel
9.1 Chapter Overview
9.2 Retail and Specialty Pharmacies
9.2.1 Retail and Specialty Pharmacies Market Trends Analysis (2021-2032)
9.2.2 Retail and Specialty Pharmacies Market Size Estimates and Forecasts to 2032 (USD Billion)
9.3 Hospital Pharmacies
9.3.1 Hospital Pharmacies Market Trends Analysis (2021-2032)
9.3.2 Hospital Pharmacies Market Size Estimates and Forecasts to 2032 (USD Billion)
9.4 Other Pharmacies
9.4.1 Other Pharmacies Market Trends Analysis (2021-2032)
9.4.2 Other Pharmacies Market Size Estimates and Forecasts to 2032 (USD Billion)
10. Regional Analysis
10.1 Chapter Overview
10.2 North America
10.2.1 Trends Analysis
10.2.2 North America Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.2.3 North America Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.2.4 North America Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Disease Stage (2021-2032) (USD Billion)
10.2.5 North America Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.2.6 USA
10.2.6.1 USA Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.2.6.2 USA Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Disease Stage (2021-2032) (USD Billion)
10.2.6.3 USA Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.2.7 Canada
10.2.7.1 Canada Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.2.7.2 Canada Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Disease Stage (2021-2032) (USD Billion)
10.2.7.3 Canada Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.2.8 Mexico
10.2.8.1 Mexico Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.2.8.2 Mexico Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Disease Stage (2021-2032) (USD Billion)
10.2.8.3 Mexico Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3 Europe
10.3.1 Trends Analysis
10.3.2 Europe Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.3.3 Europe Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.3.4 Europe Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Disease Stage (2021-2032) (USD Billion)
10.3.5 Europe Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3.6 Germany
10.3.6.1 Germany Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.3.6.2 Germany Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Disease Stage (2021-2032) (USD Billion)
10.3.6.3 Germany Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3.7 France
10.3.7.1 France Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.3.7.2 France Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Disease Stage (2021-2032) (USD Billion)
10.3.7.3 France Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3.8 UK
10.3.8.1 UK Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.3.8.2 UK Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Disease Stage (2021-2032) (USD Billion)
10.3.8.3 UK Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3.9 Italy
10.3.9.1 Italy Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.3.9.2 Italy Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Disease Stage (2021-2032) (USD Billion)
10.3.9.3 Italy Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3.10 Spain
10.3.10.1 Spain Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.3.10.2 Spain Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Disease Stage (2021-2032) (USD Billion)
10.3.10.3 Spain Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3.11 Poland
10.3.11.1 Poland Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.3.11.2 Poland Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Disease Stage (2021-2032) (USD Billion)
10.3.11.3 Poland Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3.12 Turkey
10.3.12.1 Turkey Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.3.12.2 Turkey Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Disease Stage (2021-2032) (USD Billion)
10.3.12.3 Turkey Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.3.13 Rest of Europe
10.3.13.1 Rest of Europe Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.3.13.2 Rest of Europe Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Disease Stage (2021-2032) (USD Billion)
10.3.13.3 Rest of Europe Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.4 Asia Pacific
10.4.1 Trends Analysis
10.4.2 Asia Pacific Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.4.3 Asia Pacific Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.4.4 Asia Pacific Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Disease Stage (2021-2032) (USD Billion)
10.4.5 Asia Pacific Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.4.6 China
10.4.6.1 China Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.4.6.2 China Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Disease Stage (2021-2032) (USD Billion)
10.4.6.3 China Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.4.7 India
10.4.7.1 India Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.4.7.2 India Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Disease Stage (2021-2032) (USD Billion)
10.4.7.3 India Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.4.8 Japan
10.4.8.1 Japan Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.4.8.2 Japan Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Disease Stage (2021-2032) (USD Billion)
10.4.8.3 Japan Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.4.9 South Korea
10.4.9.1 South Korea Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.4.9.2 South Korea Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Disease Stage (2021-2032) (USD Billion)
10.4.9.3 South Korea Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.4.10 Singapore
10.4.10.1 Singapore Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.4.10.2 Singapore Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Disease Stage (2021-2032) (USD Billion)
10.4.10.3 Singapore Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.4.11 Australia
10.4.11.1 Australia Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.4.11.2 Australia Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Disease Stage (2021-2032) (USD Billion)
10.4.11.3 Australia Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.4.12 Rest of Asia Pacific
10.4.12.1 Rest of Asia Pacific Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.4.12.2 Rest of Asia Pacific Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Disease Stage (2021-2032) (USD Billion)
10.4.12.3 Rest of Asia Pacific Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.5 Middle East and Africa
10.5.1 Trends Analysis
10.5.2 Middle East and Africa Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.5.3 Middle East and Africa Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.5.4 Middle East and Africa Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Disease Stage (2021-2032) (USD Billion)
10.5.5 Middle East and Africa Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.5.6 UAE
10.5.6.1 UAE Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.5.6.2 UAE Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Disease Stage (2021-2032) (USD Billion)
10.5.6.3 UAE Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.5.7 Saudi Arabia
10.5.7.1 Saudi Arabia Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.5.7.2 Saudi Arabia Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Disease Stage (2021-2032) (USD Billion)
10.5.7.3 Saudi Arabia Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.5.8 Saudi Arabia
10.5.8.1 Saudi Arabia Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.5.8.2 Saudi Arabia Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Disease Stage (2021-2032) (USD Billion)
10.5.8.3 Saudi Arabia Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.5.9 Qatar
10.5.9.1 Qatar Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.5.9.2 Qatar Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Disease Stage (2021-2032) (USD Billion)
10.5.9.3 Qatar Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.5.10 South Africa
10.5.10.1 South Africa Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.5.10.2 South Africa Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Disease Stage (2021-2032) (USD Billion)
10.5.10.3 South Africa Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.5.11 Rest of Middle East & Africa
10.5.11.1 Rest of Middle East & Africa Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.5.11.2 Rest of Middle East & Africa Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Disease Stage (2021-2032) (USD Billion)
10.5.11.3 Rest of Middle East & Africa Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.6 Latin America
10.6.1 Trends Analysis
10.6.2 Latin America Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, by Country (2021-2032) (USD Billion)
10.6.3 Latin America Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.6.4 Latin America Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Disease Stage (2021-2032) (USD Billion)
10.6.5 Latin America Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.6.6 Brazil
10.6.6.1 Brazil Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.6.6.2 Brazil Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Disease Stage (2021-2032) (USD Billion)
10.6.6.3 Brazil Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.6.7 Argentina
10.6.7.1 Argentina Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.6.7.2 Argentina Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Disease Stage (2021-2032) (USD Billion)
10.6.7.3 Argentina Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
10.6.8 Rest of Latin America
10.6.8.1 Rest of Latin America Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Drug (2021-2032) (USD Billion)
10.6.8.2 Rest of Latin America Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Disease Stage (2021-2032) (USD Billion)
10.6.8.3 Rest of Latin America Non-alcoholic Steatohepatitis Treatment Market Estimates and Forecasts, By Distribution Channel (2021-2032) (USD Billion)
11. Company Profiles
11.1 Madrigal Pharmaceuticals Inc.
11.1.1 Company Overview
11.1.2 Financial
11.1.3 Product/ Services Offered
11.1.4 SWOT Analysis
11.2 Intercept Pharmaceuticals, Inc.
11.2.1 Company Overview
11.2.2 Financial
11.2.3 Product/ Services Offered
11.2.4 SWOT Analysis
11.3 Galmed Pharmaceuticals Ltd
11.3.1 Company Overview
11.3.2 Financial
11.3.3 Product/ Services Offered
11.3.4 SWOT Analysis
11.4 Inventiva
11.4.1 Company Overview
11.4.2 Financial
11.4.3 Product/ Services Offered
11.4.4 SWOT Analysis
11.5 Galectin Therapeutics Inc.
11.5.1 Company Overview
11.5.2 Financial
11.5.3 Product/ Services Offered
11.5.4 SWOT Analysis
11.6 Novo Nordisk A/S
11.6.1 Company Overview
11.6.2 Financial
11.6.3 Product/ Services Offered
11.6.4 SWOT Analysis
11.7 NGM Biopharmaceuticals, Inc.
11.7.1 Company Overview
11.7.2 Financial
11.7.3 Product/ Services Offered
11.7.4 SWOT Analysis
11.8 AbbVie Inc.
11.8.1 Company Overview
11.8.2 Financial
11.8.3 Product/ Services Offered
11.8.4 SWOT Analysis
11.9 The Bristol-Myers Squibb Company
11.9.1 Company Overview
11.9.2 Financial
11.9.3 Product/ Services Offered
11.9.4 SWOT Analysis
11.10 Gilead Sciences, Inc.
11.10.1 Company Overview
11.10.2 Financial
11.10.3 Product/ Services Offered
11.10.4 SWOT Analysis
12. Use Cases and Best Practices
13. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
By Drug
Vitamin E and Pioglitazone
Obeticholic Acid (OCA)
Resmetirom
Lanifibranor
Semaglutide
Cenicriviroc
Aramchol
Other Drugs
By Disease Stage
NASH Stage F0
NASH Stage F1
NASH Stage F2
NASH Stage F3
NASH Stage F4
By Distribution Channel
Retail and Specialty Pharmacies
Hospital Pharmacies
Other Pharmacies
Request for Segment Customization as per your Business Requirement: Segment Customization Request
North America
US
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Poland
Turkey
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
UAE
Saudi Arabia
Qatar
South Africa
Rest of Middle East & Africa
Latin America
Brazil
Argentina
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Detailed Volume Analysis
Criss-Cross segment analysis (e.g. Product X Application)
Competitive Product Benchmarking
Geographic Analysis
Additional countries in any of the regions
Customized Data Representation
Detailed analysis and profiling of additional market players
